Table S3 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression

Table S3 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression

<p>Gene mutation analysis identified in 50 patients with PanNETs</p>

Guardat en:

Dades bibliogràfiques
Autor principal:	Junfeng Xu (16437141) (author)
Altres autors:	Zeng Ye (16437144) (author), Qifeng Zhuo (16437147) (author), Heli Gao (16437150) (author), Yi Qin (15400233) (author), Xin Lou (16437153) (author), Wuhu Zhang (16437156) (author), Fei Wang (16437159) (author), Yan Wang (16437162) (author), Desheng Jing (16437165) (author), Guixiong Fan (16437168) (author), Yue Zhang (16437171) (author), Xuemin Chen (16437174) (author), Jie Chen (16437177) (author), Xiaowu Xu (16437180) (author), Xianjun Yu (16437183) (author), Shunrong Ji (16437186) (author)
Publicat:	2025
Matèries:	Cancer Cancer Biology Clinical Research and Trials Endocrine-Related Cancers Oncogenes & Tumor Suppressors Precision Medicine Rare Cancers
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

Table S2 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression
per: Junfeng Xu (16437141)
Publicat: (2025)

Supplementary Data from β-Catenin–Driven Differentiation Is a Tissue-Specific Epigenetic Vulnerability in Adrenal Cancer
per: Dipika R. Mohan (15011204)
Publicat: (2025)

Figure 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
per: Clare Vesely (505402)
Publicat: (2025)

Figure 2 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
per: Clare Vesely (505402)
Publicat: (2025)

Figure 3 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
per: Clare Vesely (505402)
Publicat: (2025)

Figure 4 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
per: Clare Vesely (505402)
Publicat: (2025)

Figure 5 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
per: Clare Vesely (505402)
Publicat: (2025)

Table 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
per: Clare Vesely (505402)
Publicat: (2025)

Supplementary Tables from Biallelic <i>Dicer1</i> Mutations in the Gynecologic Tract of Mice Drive Lineage-Specific Development of <i>DICER1</i> Syndrome–Associated Cancer
per: Yemin Wang (17315078)
Publicat: (2025)

Supplementary fig 1 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
per: Jiwei Bai (15051797)
Publicat: (2025)

Supplementary fig 2 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
per: Jiwei Bai (15051797)
Publicat: (2025)

Supplementary fig 3 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
per: Jiwei Bai (15051797)
Publicat: (2025)

Supplementary fig 4 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
per: Jiwei Bai (15051797)
Publicat: (2025)

Supplementary fig 5 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
per: Jiwei Bai (15051797)
Publicat: (2025)

Table S1-S5 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
per: Jiwei Bai (15051797)
Publicat: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
per: Dwight H. Owen (15034782)
Publicat: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
per: Dwight H. Owen (15034782)
Publicat: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
per: Dwight H. Owen (15034782)
Publicat: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
per: Dwight H. Owen (15034782)
Publicat: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
per: Dwight H. Owen (15034782)
Publicat: (2025)

Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
per: Evangeline R. Jackson (15558808)
Publicat: (2025)

العمل بالأكثر والغالب عند الأصوليين: دراسة تطبيقية
per: Al-mutiri, Aloush Khaled
Publicat: (2022)

Figure S7 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
per: Shiyi Yu (17079079)
Publicat: (2025)

Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
per: Gwo Yaw Ho (14961416)
Publicat: (2025)

Spreadsheet index of named bookbinders in the Sotheby's auction catalogues for the sales of the Major John Roland Abbey collection, sold between 1965 and 1989
per: John Hodgson (22668215)
Publicat: (2025)

Table S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
per: Alyssa C. Flint (16676029)
Publicat: (2025)

Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
per: Alyssa C. Flint (16676029)
Publicat: (2025)

Video 1_Imaging-driven diagnosis of retroperitoneal psoas major alveolar soft part sarcoma: a case report.mp4
per: Shasha Wei (1555588)
Publicat: (2025)

Figure S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
per: Laura Boucai (15054310)
Publicat: (2025)

Figure S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
per: Laura Boucai (15054310)
Publicat: (2025)

Figure S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
per: Laura Boucai (15054310)
Publicat: (2025)

Figure S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
per: Laura Boucai (15054310)
Publicat: (2025)

Table S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
per: Laura Boucai (15054310)
Publicat: (2025)

Table S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
per: Laura Boucai (15054310)
Publicat: (2025)

Table S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
per: Laura Boucai (15054310)
Publicat: (2025)

Table S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
per: Laura Boucai (15054310)
Publicat: (2025)

Table S5 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
per: Laura Boucai (15054310)
Publicat: (2025)

Table S6 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
per: Laura Boucai (15054310)
Publicat: (2025)

Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
per: John A. Ligon (15024477)
Publicat: (2025)

Supplementary file 1_Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.docx
per: Xiaohu Jin (9618675)
Publicat: (2025)

Cannot write session to /tmp/vufind_sessions/sess_2bajobkmod12lb2ts86gqqvdpg